©2022 Stanford Medicine
COMT Activity and Hypnotizability
Trial ID: NCT04624880
Purpose
Hypnosis is an effective pain management tool for surgery that can reduce opioid use up to
40%. COMT single nucleotide polymorphisms (SNPs) can predict pain sensitivity and opioid use
perioperatively, and may also be associated with hypnotizability or response to hypnotic
analgesia. Analyzing COMT haplotypes from DNA extracted from saliva or blood using a giant
magnetoresistive (GMR) nanotechnology platform may be faster, less expensive, and at least as
accurate as pyrosequencing. This study aims to validate a multi-SNP point-of-care (POC) GMR
assay for the rapid genotyping of SNPs predictive of COMT activity, and test the feasibility
of using COMT activity as a biomarker for hypnotizability and/or response to hypnotic
analgesia.
Official Title
COMT Activity as a Biomarker for Hypnotizability and Hypnotic Analgesia Using a Multiplexed Precision Medicine Platform
Stanford Investigator(s)
David Spiegel
Jack, Lulu and Sam Willson Professor of Medicine
Jessie (Kittle) Markovits
Clinical Associate Professor, Medicine Clinical Associate Professor (By courtesy), Psychiatry and Behavioral Sciences
Eligibility
Inclusion Criteria:
- Prior enrollment in one of 3 specific hypnosis trials
- Enrollment is by invitation only
Exclusion Criteria:
- Participants in the prior trials who declined to be contacted for future research.
Intervention(s):
device: Giant magnetoresistive sensor (GMR)
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jessie Kittle, MD
800-000-0000